Clinicopathological features and outcome in elderly patients with idiopathic membranous nephropathy

References

• Sinico RA, Mezzina N, Trezzi B, et al. Immunology of membranous nephropathy: from animal models to humans. Clin Exp Immunol. 2016;183(2):1–11.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Yang X, Wang M, et al. Changes in the diagnosis of glomerular diseases in east China: a 15-year renal biopsy study. Ren Fail. 2018;40(1):657–664.
   PubMed Web of Science ®Google Scholar
• Tang L, Yao J, Kong X, et al. Increasing prevalence of membranous nephropathy in patients with primary glomerular diseases: a cross-sectional study in China. Nephrology (Carlton). 2017;22(2):168–173.
   PubMed Web of Science ®Google Scholar
• Xu X, Ning Y, Shang W, et al. Analysis of 4931 renal biopsy data in Central China from 1994 to 2014. Ren Fail. 2016;38(7):1021–1030.
   PubMed Web of Science ®Google Scholar
• Jin B, Zeng C, Ge Y, et al. The spectrum of biopsy-proven kidney diseases in elderly chinese patients. Nephrol Dial Transplant. 2014;29(12):2251–2259.
   PubMed Web of Science ®Google Scholar
• Nie P, Lou Y, Wang Y, et al. Clinical and pathological analysis of renal biopsies of elderly patients in northeast China: a single-center study. Ren Fail. 2021;43(1):851–859.
   PubMed Web of Science ®Google Scholar
• Pan X, Xu J, Ren H, et al. Changing spectrum of biopsy-proven primary glomerular diseases over the past 15 years: a single-center study in China. Contributions to Nephrology. 2013;181:22–30.
   PubMed Web of Science ®Google Scholar
• Hou JH, Zhu HX, Zhou ML, et al. Changes in the spectrum of kidney diseases: an analysis of 40,759 Biopsy-Proven cases from 2003 to 2014 in China. Kidney Dis (Basel). 2018;4(1):10–19.
   PubMed Web of Science ®Google Scholar
• Hu R, Quan S, Wang Y, et al. Spectrum of biopsy proven renal diseases in Central China: a 10-year retrospective study based on 34,630 cases. Sci Rep. 2020;10(1):10994.
   PubMed Web of Science ®Google Scholar
• Cybulski M, Cybulski L, Krajewska-Kulak E, et al. Illness acceptance, pain perception and expectations for physicians of the elderly in Poland. BMC Geriatr. 2017;17(1):46.
   PubMedGoogle Scholar
• Tonelli M, Riella MC. World kidney day 2014: CKD and the aging population. Am J Kidney Dis. 2014;63(3):349–353.
   PubMed Web of Science ®Google Scholar
• Fraser SDS, Roderick PJ. Kidney disease in the global burden of disease study 2017. Nat Rev Nephrol. 2019;15(4):193–194.
   PubMed Web of Science ®Google Scholar
• Bae E, Lee SW, Park S, et al. Treatment and clinical outcomes of elderly idiopathic membranous nephropathy: a multicenter cohort study in korea. Arch Gerontol Geriatr. 2018;76:175–181.
   PubMed Web of Science ®Google Scholar
• Zhang XD, Cui Z, Zhang MF, et al. Clinical implications of pathological features of primary membranous nephropathy. BMC Nephrol. 2018;19(1):215.
   PubMedGoogle Scholar
• Kim Y, Yoon HE, Chung BH, et al. Clinical outcomes and effects of treatment in older patients with idiopathic membranous nephropathy. Korean J Intern Med. 2019;34(5):1091–1099.
   PubMed Web of Science ®Google Scholar
• Lin C, Zheng D, Wang Y, et al. Clinical and pathological features of idiopathic membranous nephropathy in young people. Nephrology (Carlton). 2019;24(6):599–604.
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Yamamoto R, Imai E, et al. Better remission rates in elderly japanese patients with primary membranous nephropathy in nationwide real-world practice: the Japan nephrotic syndrome cohort study (JNSCS). Clin Exp Nephrol. 2020;24(10):893–909.
   PubMed Web of Science ®Google Scholar
• Abrass CK. Treatment of membranous nephropathy in the elderly. Semin Nephrol. 2003;23(4):373–378.
   PubMed Web of Science ®Google Scholar
• Zent R, Nagai R, Cattran DC. Idiopathic membranous nephropathy in the elderly: a comparative study. Am J Kidney Dis. 1997;29(2):200–206.
   PubMed Web of Science ®Google Scholar
• Ehrenreich T, Porush JG, Churg J, et al. Treatment of idiopathic membranous nephropathy. N Engl J Med. 1976;295(14):741–746.
   PubMed Web of Science ®Google Scholar
• Group K. KDIGO clinical practice guideline for glomerulonephritis. Kidney Inter Suppl. 2012;2(2):139–274.
   Web of Science ®Google Scholar
• Alsharhan L, Beck LH.Jr. Membranous nephropathy: Core curriculum 2021. Am J Kidney Dis. 2021;77(3):440–453.
   PubMed Web of Science ®Google Scholar
• Deegens JK, Wetzels JF. Membranous nephropathy in the older adult: epidemiology, diagnosis and management. Drugs Aging. 2007;24(9):717–732.
   PubMed Web of Science ®Google Scholar
• O’Callaghan CA, Hicks J, Doll H, et al. Characteristics and outcome of membranous nephropathy in older patients. Int Urol Nephrol. 2002;33(1):157–165.
   PubMedGoogle Scholar
• Sumnu A, Gursu M, Ozturk S. Primary glomerular diseases in the elderly. World J Nephrol. 2015;4(2):263–270.
   PubMedGoogle Scholar
• Beck LH, Jr., Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21.
   PubMed Web of Science ®Google Scholar
• Radice A, Pieruzzi F, Trezzi B, et al. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases. J Nephrol. 2018;31(2):271–278.
   PubMed Web of Science ®Google Scholar
• Doi T, Mayumi M, Kanatsu K, et al. Distribution of IgG subclasses in membranous nephropathy. Clin Exp Immunol. 1984;58(1):57–62.
   PubMed Web of Science ®Google Scholar
• Qu Z, Liu G, Li J, et al. Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol Dial Transplant. 2012;27(5):1931–1937.
   PubMed Web of Science ®Google Scholar
• Kuroki A, Iyoda M, Shibata T, et al. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int. 2005;68(1):302–310.
   PubMed Web of Science ®Google Scholar
• Stangou MJ, Marinaki S, Papachristou E, et al. Histological grading in primary membranous nephropathy is essential for clinical management and predicts outcome of patients. Histopathology. 2019;75(5):660–671.
   PubMed Web of Science ®Google Scholar
• Zhang BO, Cheng M, Yang M, et al. Analysis of the prognostic risk factors of idiopathic membranous nephropathy using a new surrogate end-point. Biomed Rep. 2016;4(2):147–152.
   PubMed Web of Science ®Google Scholar
• Polanco N, Gutiérrez E, Covarsí A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697–704.
   PubMed Web of Science ®Google Scholar
• Glassock RJ. Diagnosis and natural course of membranous nephropathy. Semin Nephrol. 2003;23(4):324–332.
   PubMed Web of Science ®Google Scholar
• KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4s):S1–s276.
   PubMed Web of Science ®Google Scholar
• Cattran DC, Kim ED, Reich H, et al. Membranous nephropathy: quantifying remission duration on outcome. J Am Soc Nephrol. 2017;28(3):995–1003.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Ando M, Katsuno T, et al. Urinary protein and renal prognosis in idiopathic membranous nephropathy: a multicenter retrospective cohort study in Japan. Ren Fail. 2018;40(1):435–441.
   PubMed Web of Science ®Google Scholar
• Chen X, Chen Y, Ding X, et al. Baseline proteinuria level is associated with prognosis in idiopathic membranous nephropathy. Ren Fail. 2019;41(1):363–369.
   PubMed Web of Science ®Google Scholar
• Wada T, Ishimoto T, Nakaya I, et al. A digest of the Evidence-Based clinical practice guideline for nephrotic syndrome 2020. Clin Exp Nephrol. 2021;25(12):1277–1285.
   PubMed Web of Science ®Google Scholar
• Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381(1):36–46.
   PubMed Web of Science ®Google Scholar